PRNewsWire
14 Sept 2026, 01:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Johnson & Johnson's RYBREVANT plus chemotherapy achieved a median overall survival (OS) of 34.3 months in patients with EGFR exon 20 insertion lung cancer, the longest reported for this population. — Setting a new benchmark for survival in a difficult-to-treat cancer segment strengthens the drug's market position and long-term revenue potential.
+0.60A prespecified analysis adjusting for patient crossover showed the combination therapy reduced the risk of death by 43%. — Statistically significant risk reduction provides strong clinical validation for the drug's efficacy as a first-line treatment.
+0.40The combination therapy extended progression-free survival through second disease progression (PFS2) by more than 10 months compared to chemotherapy alone. — Durable benefit beyond the first progression suggests higher long-term patient retention and utility as a 'backbone therapy'.
+0.30Which stocks this story touches
Continue reading
5 related stories
Top 1 mover · tap to explore
The company announced positive Phase 3 trial results for RYBREVANT, achieving the longest reported median overall survival for a specific lung cancer mutation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
